As of 2024-12-13, the EV/EBITDA ratio of Basilea Pharmaceutica AG (BSLN.SW) is -83.00. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BSLN.SW's latest enterprise value is 525.45 mil CHF. BSLN.SW's TTM EBITDA according to its financial statements is -6.33 mil CHF. Dividing these 2 quantities gives us the above BSLN.SW EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 4.8x - 7.2x | 7.0x |
| Forward P/E multiples | 7.1x - 12.6x | 7.3x |
| Fair Price | (5.23) - 17.80 | 1.42 |
| Upside | -112.9% - -56.2% | -96.5% |
| Date | EV/EBITDA |
| 2024-12-04 | -81.94 |
| 2024-12-03 | -83.47 |
| 2024-12-02 | -83.57 |
| 2024-11-29 | -85.01 |
| 2024-11-28 | -84.43 |
| 2024-11-27 | -83.38 |
| 2024-11-26 | -82.90 |
| 2024-11-25 | -85.77 |
| 2024-11-22 | -84.24 |
| 2024-11-21 | -82.80 |
| 2024-11-20 | -82.42 |
| 2024-11-19 | -81.27 |
| 2024-11-18 | -81.37 |
| 2024-11-15 | -81.75 |
| 2024-11-14 | -83.09 |
| 2024-11-13 | -83.67 |
| 2024-11-12 | -84.05 |
| 2024-11-11 | -85.20 |
| 2024-11-08 | -85.96 |
| 2024-11-07 | -86.54 |
| 2024-11-06 | -86.73 |
| 2024-11-05 | -87.69 |
| 2024-11-04 | -88.74 |
| 2024-11-01 | -87.88 |
| 2024-10-31 | -87.11 |
| 2024-10-30 | -88.45 |
| 2024-10-29 | -88.74 |
| 2024-10-28 | -90.46 |
| 2024-10-25 | -91.04 |
| 2024-10-24 | -89.79 |
| 2024-10-23 | -90.65 |
| 2024-10-22 | -90.18 |
| 2024-10-21 | -91.32 |
| 2024-10-18 | -92.47 |
| 2024-10-17 | -90.94 |
| 2024-10-16 | -91.23 |
| 2024-10-15 | -91.80 |
| 2024-10-14 | -92.57 |
| 2024-10-11 | -92.09 |
| 2024-10-10 | -91.61 |
| 2024-10-09 | -90.27 |
| 2024-10-08 | -90.46 |
| 2024-10-07 | -91.42 |
| 2024-10-04 | -90.85 |
| 2024-10-03 | -91.23 |
| 2024-10-02 | -91.61 |
| 2024-10-01 | -92.47 |
| 2024-09-30 | -93.91 |
| 2024-09-27 | -94.20 |
| 2024-09-26 | -95.34 |